Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any ...

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

Tarlatamab (IMDYLLTRA, Amgen) is indicated for 'the treatment of adult patients with extensive-stage small-cell lung cancer (ES‑SCLC) with disease progression on or after at least two prior lines of ...

Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults ...

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

Tarlatamab (Imdylltra) is not normally available on the NHS for treating extensive-stage small-cell lung cancer in adults whose cancer has got worse after 2 or more lines of treatment, including ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on tarlatamab for previously treated advanced small-cell lung cancer [ID6364] and ...

Tarlatamab should not be used to treat extensive-stage small-cell lung cancer in adults whose cancer has progressed after 2 or more lines of treatment, including platinum-based chemotherapy.

Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults ...